Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Informed. Stay Competitive with FREE Updates

Get Free Email Updates

J&J’s Janssen Pharmaceutical Companies To Provide 200k Ebola Vaccine Regimens to the Republic of Rwanda

By John F. Heerdink, Jr.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Reportedly, Johnson & Johnson’s Janssen Pharmaceutical Companies is set to provide 200k Ebola vaccine regimens to the Republic of Rwanda. Recently, a new immunization program was initiated by the Rwanda Government to help protect the country’s citizens from the Ebola outbreak in the neighboring Democratic Republic of the Congo (DRC). The World Health Organization (WHO) declared the DRC Ebola outbreak a Public Health Emergency of International Concern on July 17, 2019, reporting more than 3000 cases including 2200 deaths to date.

“Johnson & Johnson recognizes the Rwandan Government’s decision to proactively deploy Janssen’s investigational Ebola vaccine to help prevent the spread of the disease into the country. We stand ready to support Rwanda’s initiative on epidemic preparedness.” stated Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson.

Johnson & Johnson has made a major investment in Janssen’s Ebola vaccine regimen after the development program in 2014 to aid the widespread outbreak that occurred in West Africa that year. The company has been continuously committed to global pandemic preparedness awareness and has been actively participating across multiple disease areas.

The Janssen vaccine consists of two doses leveraging different vaccines inducing robust and long-lasting immunity and has been developed in a collaborative research program with the NIH and received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.

nov3(12)

Post View Count : 162
(Read Original Story: Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak in PR Newswire)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us